Skip to content

COG+OT Telerehabilitation for Adults With Subjective Cognitive Complaints

A Comprehensive Cognitive Assessment Protocol and Innovative Neurocognitive Telerehabilitation Pilot Program for Adults With Subjective Cognitive Complaints

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07743229
Acronym
CogSCC
Enrollment
16
Registered
2026-08-03
Start date
2026-10-01
Completion date
2027-05-01
Last updated
2026-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Dysfunction, Ehlers-Danlos Syndrome, Subjective Cognitive Complaints

Keywords

Subjective cognitive complaints, Brain fog, Functional cognition, Occupational therapy, Cognitive rehabilitation, Ehlers-Danlos Syndrome

Brief summary

This pilot study will evaluate a comprehensive cognitive assessment approach and personalized neurocognitive telerehabilitation intervention for adults with subjective cognitive complaints (SCC). The study includes older adults with SCC and adults with Ehlers-Danlos Syndrome (EDS) and SCC. Participants will complete pre- and post-treatment assessments and receive a 6-week COG+OT telerehabilitation intervention that combines cognitive rehabilitation and occupational therapy strategies to support everyday functional cognition.

Interventions

BEHAVIORALCOG+OT Telerehabilitation

COG+OT is a personalized telerehabilitation program that combines cognitive rehabilitation and occupational therapy. Cognitive rehabilitation sessions focus on strategies for attention, memory, organization, planning, problem solving, and executive function. Occupational therapy sessions use meaningful daily activities to support application and generalization of cognitive strategies in home- and community-based tasks. The intervention is delivered remotely over 6 weeks in 10 sessions lasting approximately 45 to 60 minutes each.

Sponsors

Medical University of South Carolina
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Endorsement of subjective cognitive complaints as indicated by a score ≥4 on the Healthy Brain 9 (HB9) * Community-dwelling adult aged 60 years or older, or adult aged 21 years or older with a diagnosis of Ehlers-Danlos Syndrome (EDS) * English as the primary language * Access to and ability to use a smartphone compatible with the NeuroUX platform * Access to a device capable of supporting a telerehabilitation visit, such as a phone, tablet, or laptop, and a reliable Wi-Fi or cellular internet connection * Able to participate in study assessment sessions as determined by the licensed, experienced telerehabilitation occupational therapist

Exclusion criteria

* Diagnosis of dementia or mild cognitive impairment * Significant or unstable conditions or treatments for medical conditions that may impact cognition, such as traumatic brain injury or brain tumor * Inability to engage in study-related procedures as determined by the study team

Design outcomes

Primary

MeasureTime frameDescription
Change in Everyday Cognition Scale-II (ECog-II) ScorePre-treatment to post-treatment, approximately 8 weeksChange in subjective cognition measured using the Everyday Cognition Scale-II (ECog-II), a self-report measure assessing perceived cognitive functioning across everyday activities, including memory, executive function, language, and attention.

Secondary

MeasureTime frameDescription
Retention RateThrough study completion, approximately 8 weeksFeasibility measured as the percentage of participants who complete all study sessions.
Adherence RateThrough study completion, approximately 8 weeksFeasibility measured as the percentage of participants completing intervention activities for each session, including functional task practice and homework.

Countries

United States

Contacts

CONTACTPatricia Finetto, OTR/L
piersonp@musc.edu843-792-8533
CONTACTMichelle Woodbury, PhD, OTR/L
woodbuml@musc.edu
PRINCIPAL_INVESTIGATORMichelle Woodbury, PhD, OTR/L

Medical University of South Carolina

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 10, 2026